A Phase 2 interventional study of Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Hoffmann-La Roche. Completed at 56 sites in 13 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-11-12.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Idiopathic Pulmonary Fibrosis · Hoffmann-La Roche.
Among the 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche, this one is the 12th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2016, is one of 9 in phase 2, and was the 23rd registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →None of the 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche is open now. The open studies under Idiopathic Pulmonary Fibrosis, anywhere →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 177 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 150 across the 24 interventional studies, 204 across the 4 observational. Of the 27 that completed or were terminated, 15 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase IIb, randomized, placebo-controlled, multicenter, international study will evaluate the efficacy, safety, and tolerability of sildenafil or placebo added to pirfenidone (Esbriet) treatment in participants with advanced IPF and intermediate or high probability of Group 3 pulmonary hypertension (PH) who are on a stable dose of pirfenidone with demonstrated tolerability. Participants will be randomized to receive 1 year of treatment with either oral sildenafil or matching placebo while continuing to take pirfenidone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive pirfenidone along with placebo matched to sildenafil, orally, three times a day (TID) for 52 weeks.
Drug: Pirfenidone · Drug: Placebo
Participants will receive pirfenidone along with sildenafil, orally, TID for 52 weeks.
Drug: Pirfenidone · Drug: Sildenafil
Pirfenidone will be given in the range of 1602 to 2403 milligram per day (mg/day), as 3 divided doses.
Also known as: Esbriet, RO0220912
Placebo matched with sildenafil.
Sildenafil will be given as 20 mg, TID.
Also known as: RO0280296
Percentage of Participants With Disease Progression, as Determined by Relevant Decline in 6 Minute Walk Distance (6MWD) of At Least (>=) 15 Percent (%) From Baseline, Respiratory-Related Non-Elective Hospitalization, or Death From Any Cause
Disease Progression defined as relative decline in 6-minute walking distance (6MWD) from baseline (defined as \>25% from baseline or 15-25% from baseline associated with worsening oxygen saturation, worsening Borg score, or increased oxygen requirements), respiratory-related non-elective hospitalizations, or all-cause mortality.
Time frame: Baseline up to Week 52
Time to First Occurrence of Disease Progression
Disease Progression defined as relative decline in 6MWD from baseline (defined as \>25% from baseline or 15-25% from baseline associated with worsening oxygen saturation, worsening Borg score, or increased oxygen requirements), respiratory-related non-elective hospitalizations, or all-cause mortality.
Time frame: Baseline up to Week 52
Time to Multiple Occurrence of Disease Progression Events
Disease Progression defined as relative decline in 6MWD from baseline (defined as \>25% from baseline or 15-25% from baseline associated with worsening oxygen saturation, worsening Borg score, or increased oxygen requirements), respiratory-related non-elective hospitalizations, or all-cause mortality. In case participant had more than one event as described in the endpoint definition the second, third etc event was counted as well for the calculation of the endpoint.
Time frame: Baseline up to Week 52
Percentage of Participants With Decline From Baseline in 6-minute Walking Distance (6MWD) of >= 15%
Time frame: Baseline up to Week 52
Time to First Occurrence of Relevant ≥15% Decline From Baseline in 6-minute Walking Distance (6MWD)
Time frame: Baseline up to Week 52
Time to Respiratory-Related Non-Elective Hospitalization From Baseline to Week 52
N.A. = non-calculable
Time frame: Baseline up to Week 52
Time to All-Cause Non-Elective Hospitalization
N.A. = non-calculable
Time frame: Baseline up to Week 52
Time to Death From Any Cause
Time frame: Baseline up to Week 52
Percentage of Participants With Lung Transplantation
Time frame: Baseline up to Week 52
Time to Respiratory-Related Death
Time frame: Baseline up to Week 52
Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Peak Tricuspid Regurgitation Velocity
Time frame: Baseline, Week 52
Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Pulmonary Artery Pressure (PAPs)
Time frame: Baseline, Week 52
Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Tricuspid Annular Plane Systolic Excursion (TAPSE)
Time frame: Baseline, Week 52
Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Right Ventricle Basal Diameter
Time frame: Baseline, Week 52
Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Inferior Vena Cava Diameter
Time frame: Baseline, Week 52
Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Left Ventricular Ejection Fraction (LVEF)
Time frame: Baseline, Week 52
Change From Baseline to Week 52 in Carbon Monoxide Diffusing Capacity/ Pulmonary Diffusing Capacity (DLCO)
Time frame: Baseline, Week 52
Change From Baseline to Week 52 in Forced Vital Capacity (FVC)
Time frame: Baseline, Week 52
Percentage of Participants by World Health Organization (WHO) Functional Class at Week 52
The World Health Organisation (WHO) functional class system defines the severity of an participant's symptoms. Class II - Participants with Pulmonary Hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue breathlessness, fatigue (tiredness), or activities that can cause chest pain, dizziness or even black outs. Class III - Participants with Pulmonary Hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue breathlessness, fatigue (tiredness), or activities that can cause chest pain, dizziness or even black outs. Class IV - participants with pulmonary hypertension with inability to carry out any physical activity without symptoms. These participants manifest signs of right heart failure, breathlessness and /or fatigue, which may even be present at rest. Discomfort is increased by any physical activity.
Time frame: Week 52
Change From Baseline in N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Level (pg/mL) at Week 52
Time frame: Baseline, Week 52
St. George's Respiratory Questionnaire (SGRQ) Changes From Baseline at Week 52
The SGRQ is a 50-item questionnaire developed to measure health status (quality of life) in participants with diseases of airways obstruction. Three component scores are calculated, where the higher the component result the worse the condition: Symptoms concerned with the effect of respiratory symptoms, their frequency and severity (range: 0-16.61) Activity concerned with activities that cause or are limited by breathlessness (range: 0-30.31) Impacts covers a range of aspects concerned with social functioning and psychological disturbances resulting from airway disease (range: 0- 53.08) Total score summaries the impact of disease on overall health status. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
Time frame: Baseline, Week 52
University of California, San Diego-Shortness of Breath Questionnaire (UCSD-SOBQ) Changes From Baseline at Week 52
The UCSD-SOBQ is a respiratory questionnaire and it assesses dyspnea associated with activities of daily living (ADL). Participants indicate severity of SOB on a 6-point scale in 21 ADL. Three additional questions ask about fear of harm from overexertion, limitations and fear caused by SOB. A total score ranges from 0 to 120, with higher scores indicating greater impairment.
Time frame: Baseline, Week 52
Change From Baseline in Distance Walked, 6-minute Walking Distance (6MWD) Test at Week 52
Time frame: Baseline up to Week 52
Change From Baseline in Oxygen Requirements, 6-minute Walking Distance (6MWD) Test at Week 52
Time frame: Baseline up to Week 52
Change From Baseline in Other 6-minute Walking Distance (6MWD) Parameters at Week 52
Time frame: Baseline up to Week 52
Percentage of Participants With Adverse Events
Time frame: Baseline up to Week 52 + 28 days
Borg Scale Result at the End of the Test at Week 52
The Borg Scale rates participant's level of perceived exertion during any activity from 0-10, with 0 being no effort at all and 10 being maximal exertion.
Time frame: Week 52
| Milestone | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Started | 88 | 89 |
| Completed | 16 | 6 |
| Not completed | 72 | 83 |
| Withdrew: Adverse event | 3 | 7 |
| Withdrew: Death | 28 | 36 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Lung transplantation | 9 | 6 |
| Withdrew: Other | 1 | 3 |
| Withdrew: Progressive disease | 1 | 1 |
| Withdrew: Withdrawal by subject | 7 | 11 |
| Withdrew: Participant ongoing in the study | 23 | 17 |
Disease Progression defined as relative decline in 6-minute walking distance (6MWD) from baseline (defined as \>25% from baseline or 15-25% from baseline associated with worsening oxygen saturation, worsening Borg score, or increased oxygen requirements), respiratory-related non-elective hospitalizations, or all-cause mortality.
| Percentage of Participants | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Percentage of Participants With Disease Progression, as Determined by Relevant Decline in 6 Minute Walk Distance (6MWD) of At Least (>=) 15 Percent (%) From Baseline, Respiratory-Related Non-Elective Hospitalization, or Death From Any Cause | 72.7 | 69.7 |
Disease Progression defined as relative decline in 6MWD from baseline (defined as \>25% from baseline or 15-25% from baseline associated with worsening oxygen saturation, worsening Borg score, or increased oxygen requirements), respiratory-related non-elective hospitalizations, or all-cause mortality.
| Weeks | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Time to First Occurrence of Disease Progression | 26.00 (20.57 to 38.14) | 25.43 (13.00 to 37.71) |
Disease Progression defined as relative decline in 6MWD from baseline (defined as \>25% from baseline or 15-25% from baseline associated with worsening oxygen saturation, worsening Borg score, or increased oxygen requirements), respiratory-related non-elective hospitalizations, or all-cause mortality. In case participant had more than one event as described in the endpoint definition the second, third etc event was counted as well for the calculation of the endpoint.
| Weeks | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Time to Multiple Occurrence of Disease Progression Events | 20.57 (13.14 to 26.43) | 13.29 (12.71 to 23.29) |
| Percentage | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Percentage of Participants With Decline From Baseline in 6-minute Walking Distance (6MWD) of >= 15% | 53.4 | 50.6 |
| Weeks | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Time to First Occurrence of Relevant ≥15% Decline From Baseline in 6-minute Walking Distance (6MWD) | 39.00 (27.86 to 52.14) | 38.71 (25.14 to 52.57) |
N.A. = non-calculable
| Weeks | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Time to Respiratory-Related Non-Elective Hospitalization From Baseline to Week 52 | 54.29 (36.29 to NA) | NA (42.14 to NA) |
N.A. = non-calculable
| Weeks | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Time to All-Cause Non-Elective Hospitalization | 47.57 (28.00 to NA) | 49.86 (32.00 to NA) |
| Weeks | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Time to Death From Any Cause | NA (54.43 to NA) | NA (NA to NA) |
| Percentage | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Percentage of Participants With Lung Transplantation | 10.2 | 6.7 |
| Weeks | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Time to Respiratory-Related Death | NA (54.43 to NA) | NA (NA to NA) |
| m/s | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Peak Tricuspid Regurgitation Velocity | -0.014 ± 0.6326 | 0.103 ± 0.6699 |
| mmHg | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Pulmonary Artery Pressure (PAPs) | 2.0 ± 15.65 | 3.6 ± 22.38 |
| cm | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Tricuspid Annular Plane Systolic Excursion (TAPSE) | -0.204 ± 0.4170 | -0.146 ± 0.4453 |
| cm | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Right Ventricle Basal Diameter | 0.462 ± 1.2305 | 0.095 ± 1.2875 |
| cm | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Inferior Vena Cava Diameter | -0.05 ± 0.595 | -0.09 ± 0.540 |
| Percentage | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Left Ventricular Ejection Fraction (LVEF) | 1.22 ± 9.166 | -0.85 ± 5.767 |
| Percentage Predicted | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Change From Baseline to Week 52 in Carbon Monoxide Diffusing Capacity/ Pulmonary Diffusing Capacity (DLCO) | -2.918 ± 6.2296 | -2.440 ± 8.2820 |
| Percentage Predicted | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Change From Baseline to Week 52 in Forced Vital Capacity (FVC) | -2.761 ± 7.8044 | -1.616 ± 11.1158 |
The World Health Organisation (WHO) functional class system defines the severity of an participant's symptoms. Class II - Participants with Pulmonary Hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue breathlessness, fatigue (tiredness), or activities that can cause chest pain, dizziness or even black outs. Class III - Participants with Pulmonary Hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue breathlessness, fatigue (tiredness), or activities that can cause chest pain, dizziness or even black outs. Class IV - participants with pulmonary hypertension with inability to carry out any physical activity without symptoms. These participants manifest signs of right heart failure, breathlessness and /or fatigue, which may even be present at rest. Discomfort is increased by any physical activity.
| Percentage | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Class II | 19.3 | 13.5 |
| Class III | 33.0 | 24.7 |
| Class IV | 3.4 | 1.1 |
| Missing | 0 | 1.1 |
| pg/mL) | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Change From Baseline in N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Level (pg/mL) at Week 52 | 110.1 ± 612.98 | 605.9 ± 1273.19 |
The SGRQ is a 50-item questionnaire developed to measure health status (quality of life) in participants with diseases of airways obstruction. Three component scores are calculated, where the higher the component result the worse the condition: Symptoms concerned with the effect of respiratory symptoms, their frequency and severity (range: 0-16.61) Activity concerned with activities that cause or are limited by breathlessness (range: 0-30.31) Impacts covers a range of aspects concerned with social functioning and psychological disturbances resulting from airway disease (range: 0- 53.08) Total score summaries the impact of disease on overall health status. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
| Units on a scale | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Total score | 6.149 ± 12.3407 | 11.437 ± 12.5187 |
| Symptoms component score | 2.498 ± 19.6074 | 8.261 ± 19.5558 |
| Activities component score | 3.997 ± 15.4341 | 10.871 ± 14.5246 |
| Impacts component score | 8.417 ± 15.0040 | 12.118 ± 15.3487 |
The UCSD-SOBQ is a respiratory questionnaire and it assesses dyspnea associated with activities of daily living (ADL). Participants indicate severity of SOB on a 6-point scale in 21 ADL. Three additional questions ask about fear of harm from overexertion, limitations and fear caused by SOB. A total score ranges from 0 to 120, with higher scores indicating greater impairment.
| Points on scale | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| University of California, San Diego-Shortness of Breath Questionnaire (UCSD-SOBQ) Changes From Baseline at Week 52 | 12.5 ± 20.93 | 18.8 ± 19.68 |
| meters | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Change From Baseline in Distance Walked, 6-minute Walking Distance (6MWD) Test at Week 52 | -52.9 ± 121.07 | -40.8 ± 91.26 |
| L | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Change From Baseline in Oxygen Requirements, 6-minute Walking Distance (6MWD) Test at Week 52 | 0.6 ± 1.27 | 0.6 ± 1.43 |
| Percentage | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| SpO2 before the test (at rest) | -0.5 ± 4.63 | -0.8 ± 3.77 |
| SpO2 lowest during the test | -3.4 ± 8.93 | 0.3 ± 5.27 |
| SpO2 after the test | 0.5 ± 9.97 | -2.3 ± 6.67 |
| Percentage | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Percentage of Participants With Adverse Events | 98.9 | 93.3 |
The Borg Scale rates participant's level of perceived exertion during any activity from 0-10, with 0 being no effort at all and 10 being maximal exertion.
| Points on Scale | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Borg Scale Result at the End of the Test at Week 52 | 0.9 ± 3.00 | 0.7 ± 3.24 |
Collected over From baseline to primary data cut-off (up to 2 years 7 months). The safety data includes DBP and SFU up to 11-Nov-2019.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pirfenidone+Sildenafil | 28/88 (31.8%) | 54/88 (61.4%) | 53/88 (60.2%) |
| Pirfenidone+Placebo | 36/89 (40.4%) | 55/89 (61.8%) | 58/89 (65.2%) |
| Event | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 19/88 | 21/89 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/88 | 5/89 |
| PneumoniaInfections and infestations | 7/88 | 4/89 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 5/88 | 3/89 |
| Lower respiratory tract infectionInfections and infestations | 4/88 | 1/89 |
| Pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 4/88 | 2/89 |
| Cardiac arrestCardiac disorders | 1/88 | 4/89 |
| Right ventricular failureCardiac disorders | 3/88 | 1/89 |
| DeathGeneral disorders | 3/88 | 1/89 |
| Respiratory tract infectionInfections and infestations | 2/88 | 1/89 |
| Event | Pirfenidone+Sildenafil | Pirfenidone+Placebo |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 22/88 | 17/89 |
| DiarrhoeaGastrointestinal disorders | 11/88 | 2/89 |
| Respiratory tract infectionInfections and infestations | 9/88 | 4/89 |
| BronchitisInfections and infestations | 6/88 | 9/89 |
| Decreased appetiteMetabolism and nutrition disorders | 6/88 | 9/89 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/88 | 9/89 |
| HypotensionVascular disorders | 6/88 | 9/89 |
| FatigueGeneral disorders | 8/88 | 6/89 |
| Upper respiratory tract infectionInfections and infestations | 8/88 | 2/89 |
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 8/88 | 7/89 |
ITT Population -
| Age, Continuous(Years) | Pirfenidone+Sildenafil | Pirfenidone+Placebo | Total |
|---|---|---|---|
| Mean | 68.2 ± 7.7 | 68.9 ± 7.1 | 68.6 ± 7.4 |
| Sex: Female, Male(Participants) | Pirfenidone+Sildenafil | Pirfenidone+Placebo | Total |
|---|---|---|---|
| Female | 19 | 24 | 43 |
| Male | 69 | 65 | 134 |
| Ethnicity (NIH/OMB)(Participants) | Pirfenidone+Sildenafil | Pirfenidone+Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 5 |
| Not Hispanic or Latino | 78 | 79 | 157 |
| Unknown or Not Reported | 8 | 7 | 15 |
| Race (NIH/OMB)(Participants) | Pirfenidone+Sildenafil | Pirfenidone+Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 0 | 1 | 1 |
| White | 85 | 88 | 173 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2016 to primary completion in Sep 2019, 32 months.
Results were first posted in Nov 2020, 1 year 1 month after primary completion.
Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 32 months is above that.
Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Idiopathic Pulmonary Fibrosis →